←
Mitchell Tang43 posts
Mitchell Tang avatar

Mitchell Tang

@MitchellTang1

PhD student in health policy & management @Harvard @HarvardHBS studying innovation in health care. @Penn, @BCG, & Franklin elementary alum

◷ Joined June 2017▧ 2 Photos and videos
HMS HCP avatar
⟳ Mitchell Tang retweeted
HMS HCP@HMSHCP·22 Apr 2024

Telemedicine use expanded during COVID, but with key rules expiring soon, patients could lose access to care. HCP Prof. Ateev Mehrotra @Ateevm discusses a new @Health_Affairs study on telemedicine's impact & why keeping these rules is vital. @harvardmed hcp.hms.harvard.edu/news/tel…

Mitchell Tang avatar
Mitchell Tang@MitchellTang1·3 Apr 2024

Instead of treating these fees as direct practice expense, we believe AI tools should be viewed like EHRs and treated as indirect expense. That is more reflective of how clinicians are truly paying for AI, given growing use of subscription models.

Mitchell Tang avatar
Mitchell Tang@MitchellTang1·3 Apr 2024

Payment for these services is largely driven by “analysis fees” charged by AI companies. We think this is the wrong strategy.

Mitchell Tang avatar
Mitchell Tang@MitchellTang1·3 Apr 2024

We focus on two AI services which are gaining traction: FFRCT and autonomous diabetic retinopathy screening. Already, we are seeing substantial growth in payment for these services in both Medicare and commercial payers.

Post attachment
Mitchell Tang avatar
Mitchell Tang@MitchellTang1·3 Apr 2024

Amidst growing enthusiasm for AI in healthcare, there are open questions on how we should pay for AI services. In a new piece at @Health_Affairs we weigh in. healthaffairs.org/content/fo…

Health Affairs avatar
⟳ Mitchell Tang retweeted
Health Affairs@Health_Affairs·1 Apr 2024

In their new Forefront article, @MitchellTang1, Kaylee Wilson, and @Ateevm from @Harvard and @tufts argue that AI tools should be viewed as analogous to electronic health records and treated as indirect expenses. bit.ly/4cz0jLK

Mitchell Tang avatar
Mitchell Tang@MitchellTang1·7 Nov 2023

Results suggest both promise and complexities of RPM coverage and the importance of evidence-based reimbursement policy in this context.

Mitchell Tang avatar
Mitchell Tang@MitchellTang1·7 Nov 2023

Benefits were largest for patients with poor medication adherence and largely in first few months of RPM. Appropriate patient targeting and time-limited use likely would improve RPM’s value.

Mitchell Tang avatar
Mitchell Tang@MitchellTang1·7 Nov 2023

Comparing outcomes over time at RPM-adopting practices to matched non-adopting practices, we find RPM use increased medication use and medication adjustment and reduced ED visits and hospitalizations. However, it also led to increased visits and net spending.

Mitchell Tang avatar
Mitchell Tang@MitchellTang1·7 Nov 2023

Many tout RPM as a game changer for improving care of chronic diseases; others warn it could increase spending. We find evidence for both perspectives.